Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of fosmanogepix versus caspofungin followed by fluconazole in adults with candidemia or invasive candidiasis
MOH_2024-09-16_013525Phase 3Not yet recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosmanogepix in candidemia and invasive candidiasis (2 arms), sponsored by Basilea Pharmaceutica. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on MOH_2024-09-16_013525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-16_013525.